AMBALALSA share price, P/E, ROE & financials

On 6 Nov 2026, Ambalal Sarabhai Enterprises was priced at ₹35.27, or 20.7× trailing earnings, against an industry P/E of 28.7×, and the shares are 29% below their 52-week high. Its ROCE of 12% is the second-lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales and net profit grew 5.8% and 16% a year over 3 years. Debt is 0.36× equity. It is a small-cap company with a market cap of ₹270 Cr, ranked 87th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 5.8% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹36.00
Day high: ₹36.00
Day low: ₹35.06
Prev. close: ₹36.90
Volume: 36.9K

Health check

1 good · 2 fair · 3 to check

ReturnsBehind
+5.8% over a year, better than 1 of 7 peers.
Price tagCheaper
P/E 20.7 vs industry 28.7.
GrowthSteady
Sales +5.8%, profit +15.9% a year over 3 years.
ProfitabilityWeak
ROCE 12.4% vs peer median 17.9%.
Balance sheetFair
Debt 0.36× equity, interest covered 5.6×, Piotroski 5 of 9.
Red flags2 to check
Quarterly profit down 51.7% on a year ago.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹270 Cr, #87 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹206 Cr · profit ₹14 Cr

Market cap: ₹270 Cr; Small cap
P/E: 20.7; Industry 28.7
Price to book: 1.71; Peers 4.99
Dividend yield: 0.00%
ROE: 11.9%; Peers 14.7%
ROCE: 12.4%; Peers 17.9%
Debt to equity: 0.36; Debt ₹57 Cr
EPS (TTM): ₹1.70; Face value ₹10
OPM (TTM): 8.2%; Net margin 6.6%
Sales growth: −7.3%; Latest quarter vs a year ago
Profit growth: −51.7%; Latest quarter vs a year ago
Price to sales: 1.31; EV/EBITDA 17.0

Strengths

P/E of 20.7 against an industry P/E of 28.7.

Risks to check

Quarterly profit down 51.7% on a year ago.
Quarterly sales down 7.3% on a year ago.

Derived automatically from reported figures. Not a recommendation.

About Ambalal Sarabhai Enterprises

Ambalal Sarabhai Enterprises Limited, together with its subsidiaries, manufactures and markets pharmaceutical, molecular diagnostics, and electronic products in India and internationally. The company is involved in the supply of pharmaceutical preparations, such as finished dosage forms and active pharmaceutical ingredients; manufacture of fermentation-based pharmaceutical products; and manufacturing and marketing analytical, laboratory, and test and…

Headquarters: Ahmedabad
Sector: Healthcare
ISIN: INE432A01017
Website: ase.life

Price range

52 weeks

₹30.15₹49.98

Today

₹35.06₹36.00

Avg volume (3M): 92.5K
1-year return: plus 5.8%
From 52-week high: minus 29.4%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
AMBALALSAAmbalal Sarabhai Enterprises	35.27	minus 4.42%	270	20.7	1.71	12.4%	11.9%	8.2%	5.8%	15.9%	0.00%	plus 5.8%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
47	44.4	52	65.5	43.6
37.1	43.9	47.9	59.8	37
9.8	0.5	4.1	5.7	6.6
20.9%	1.1%	7.8%	8.7%	15.1%
−0	1.5	2.8	3	0.4
1	1	0.7	1.4	1
0.9	1.1	1	1	1.3
–	–	−0.8	–	–
7.9	−0	4.4	6.3	4.7
−3.7%	−1333.0%	16.5%	−4.0%	15.0%
8.2	−0.6	3.1	6.5	4
1.07	-0.07	0.40	0.85	0.52

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +5.8%
Profit CAGR 3Y: +15.9%
EPS CAGR 3Y: +15.9%
ROE: 11.9%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
170	173	195	201
–	+2.0%	+12.9%	+2.9%
160	164	182	181
9.8	8.8	13.2	20.2
5.8%	5.1%	6.8%	10.1%
11.1	7.1	7.3	7
2.4	5.7	4.2	4.1
2.8	3.6	4	3.9
−0.6	0	−7.4	−0.7
15.2	6.7	4.8	18.5
24.5%	14.6%	−2.0%	3.8%
11.4	5.7	4.9	17.8
–	minus 50.4%	minus 13.2%	+261.0%
1.49	0.74	0.64	2.32

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
76.6	76.6	76.6	76.6
54.3	59.8	63.3	81.7
45.2	46.1	50.9	56.5
69.6	67	80.8	66.2
246	250	272	281
64.5	63	62.8	66.6
3.8	–	0	2.2
3.7	5.3	18	14.4
25.2	26.7	8.7	16.6
148	154	182	181
246	250	272	281

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
5.7	8.9	−17.6	13.4
−16.8	−5.3	13.3	−10.3
9.1	−2.9	−1.5	−1.8
−2	0.6	−5.9	1.3
−20.7	−2.9	−2.7	−6.1
−14.9	6	−20.3	7.3

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 0.0% (Yahoo estimate).

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you